Spotlight

UCL cancer immunotherapy company, Autolus, launches with £30m investment

A new UCL spin-out company – Autolus – is being launched today to develop and commercialise a new generation of engineered T-cell therapies for haematological and solid tumours, with the backing of £30m in investment from healthcare investment company Syncona.

Find out more



follow us on twitter


Mariana Trejo

Knowledge Exchange Manager, Office of the Vice-Provost (Enterprise)

Knowledge Exchange Manager, Office of the Vice-Provost (Enterprise)

T:  020 3108 5071
E: m.trejo@ucl.ac.uk

Mariana manages all the enterprise funding streams – including HEIF, and the Impact Acceleration Accounts from the EPSRC, NERC and STFC - that are run out of the Office of the Vice-Provost (Enterprise). She is also responsible for managing the process for gathering Enterprise institutional management information, including quarterly KPIs from all enterprise areas and the annual reporting to the HESA and HEFCE.

Before joining OVPE, Mariana was the SLMS School Co-ordinator for REF 2014 at UCL and before that she worked for the Pro-Vice-Chancellor (Research) at Sussex University.